Geoff Meacham
Stock Analyst at Citigroup
(4.39)
# 346
Out of 5,090 analysts
279
Total ratings
60.57%
Success rate
13.99%
Average return
Main Sectors:
Stocks Rated by Geoff Meacham
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JANX Janux Therapeutics | Maintains: Buy | $58 → $49 | $17.01 | +188.07% | 3 | Dec 2, 2025 | |
| PFE Pfizer | Reinstates: Neutral | $26 | $25.89 | +0.42% | 7 | Dec 2, 2025 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $9 → $8 | $1.92 | +316.67% | 6 | Nov 18, 2025 | |
| PTGX Protagonist Therapeutics | Maintains: Buy | $96 → $98 | $90.60 | +8.17% | 3 | Nov 10, 2025 | |
| PTCT PTC Therapeutics | Maintains: Neutral | $50 → $75 | $77.20 | -2.85% | 10 | Nov 5, 2025 | |
| ABBV AbbVie | Maintains: Neutral | $240 → $235 | $223.45 | +5.17% | 21 | Nov 3, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $660 → $700 | $706.60 | -0.93% | 24 | Oct 29, 2025 | |
| RNA Avidity Biosciences | Downgrades: Neutral | $75 → $72 | $71.28 | +1.02% | 8 | Oct 27, 2025 | |
| MRNA Moderna | Maintains: Neutral | $30 → $28 | $27.70 | +1.10% | 11 | Oct 23, 2025 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Buy | $42 → $50 | $36.01 | +38.85% | 2 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $80 | $94.76 | -15.58% | 6 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $50 | $41.57 | +20.29% | 4 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $20 | $13.94 | +43.47% | 5 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $93 | $57.65 | +61.32% | 4 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $84 → $95 | $98.83 | -3.88% | 8 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $135 | $120.97 | +11.60% | 7 | Oct 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $550 → $575 | $440.98 | +30.39% | 6 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $14 | $6.64 | +111.00% | 3 | Aug 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $305 → $310 | $321.60 | -3.61% | 13 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $125 → $135 | $180.84 | -25.35% | 15 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $42 | $38.88 | +8.02% | 3 | Jul 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $54 | $74.58 | -27.59% | 6 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $76.94 | +42.97% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $6 | $6.81 | -11.89% | 1 | Jun 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $145 → $140 | $96.85 | +44.55% | 2 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $7 → $1 | $2.21 | -54.75% | 3 | Apr 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $95 | $75.24 | +26.27% | 2 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $99 → $103 | $53.26 | +93.39% | 3 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $112 → $4 | $2.20 | +81.82% | 5 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,150 → $1,100 | $992.92 | +10.78% | 9 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $120 → $20 | $28.25 | -29.20% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $22 → $31 | $22.63 | +36.99% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $180 → $170 | $201.75 | -15.74% | 3 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $68 → $60 | $51.75 | +15.94% | 8 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $10 → $8 | $5.20 | +53.85% | 4 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $17 | $1.55 | +1,000.32% | 1 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $24 | $2.15 | +1,018.62% | 4 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $4 | $11.22 | -64.35% | 2 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $3.38 | +729.63% | 1 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $0.55 | +6,110.05% | 1 | Jul 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $35 | $3.94 | +788.32% | 4 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $525 | $27.83 | +1,786.45% | 1 | Nov 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $42 | $1.19 | +3,444.30% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $8.68 | +130.41% | 1 | Sep 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $20 | $0.50 | +3,902.40% | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underperform | $9 | $5.37 | +67.75% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $13.35 | +349.54% | 1 | Jun 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $23 | $26.31 | -12.58% | 3 | Aug 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $90 → $82 | $97.94 | -16.28% | 9 | May 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $100 → $95 | $478.06 | -80.13% | 6 | Mar 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $300 → $80 | $17.00 | +370.59% | 3 | Dec 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $135 | $155.73 | -13.31% | 2 | Aug 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $10.93 | - | 4 | May 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $20 | $3.53 | +466.57% | 4 | May 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | n/a | $10.61 | - | 2 | Apr 5, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $127 → $158 | $430.39 | -63.29% | 5 | Nov 8, 2017 |
Janux Therapeutics
Dec 2, 2025
Maintains: Buy
Price Target: $58 → $49
Current: $17.01
Upside: +188.07%
Pfizer
Dec 2, 2025
Reinstates: Neutral
Price Target: $26
Current: $25.89
Upside: +0.42%
Acumen Pharmaceuticals
Nov 18, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $1.92
Upside: +316.67%
Protagonist Therapeutics
Nov 10, 2025
Maintains: Buy
Price Target: $96 → $98
Current: $90.60
Upside: +8.17%
PTC Therapeutics
Nov 5, 2025
Maintains: Neutral
Price Target: $50 → $75
Current: $77.20
Upside: -2.85%
AbbVie
Nov 3, 2025
Maintains: Neutral
Price Target: $240 → $235
Current: $223.45
Upside: +5.17%
Regeneron Pharmaceuticals
Oct 29, 2025
Maintains: Buy
Price Target: $660 → $700
Current: $706.60
Upside: -0.93%
Avidity Biosciences
Oct 27, 2025
Downgrades: Neutral
Price Target: $75 → $72
Current: $71.28
Upside: +1.02%
Moderna
Oct 23, 2025
Maintains: Neutral
Price Target: $30 → $28
Current: $27.70
Upside: +1.10%
NewAmsterdam Pharma Company
Oct 17, 2025
Maintains: Buy
Price Target: $42 → $50
Current: $36.01
Upside: +38.85%
Oct 17, 2025
Maintains: Buy
Price Target: $60 → $80
Current: $94.76
Upside: -15.58%
Oct 17, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $41.57
Upside: +20.29%
Oct 17, 2025
Maintains: Buy
Price Target: $12 → $20
Current: $13.94
Upside: +43.47%
Oct 17, 2025
Maintains: Buy
Price Target: $78 → $93
Current: $57.65
Upside: +61.32%
Oct 13, 2025
Reinstates: Neutral
Price Target: $84 → $95
Current: $98.83
Upside: -3.88%
Oct 8, 2025
Maintains: Buy
Price Target: $125 → $135
Current: $120.97
Upside: +11.60%
Oct 2, 2025
Maintains: Buy
Price Target: $550 → $575
Current: $440.98
Upside: +30.39%
Aug 27, 2025
Upgrades: Buy
Price Target: $12 → $14
Current: $6.64
Upside: +111.00%
Aug 6, 2025
Maintains: Neutral
Price Target: $305 → $310
Current: $321.60
Upside: -3.61%
Aug 1, 2025
Maintains: Neutral
Price Target: $125 → $135
Current: $180.84
Upside: -25.35%
Jul 22, 2025
Maintains: Buy
Price Target: $40 → $42
Current: $38.88
Upside: +8.02%
Jun 25, 2025
Maintains: Buy
Price Target: $50 → $54
Current: $74.58
Upside: -27.59%
Jun 17, 2025
Initiates: Buy
Price Target: $110
Current: $76.94
Upside: +42.97%
Jun 17, 2025
Initiates: Sell
Price Target: $6
Current: $6.81
Upside: -11.89%
May 6, 2025
Maintains: Buy
Price Target: $145 → $140
Current: $96.85
Upside: +44.55%
Apr 2, 2025
Downgrades: Underperform
Price Target: $7 → $1
Current: $2.21
Upside: -54.75%
Mar 13, 2025
Initiates: Buy
Price Target: $95
Current: $75.24
Upside: +26.27%
Feb 20, 2025
Maintains: Buy
Price Target: $99 → $103
Current: $53.26
Upside: +93.39%
Jan 7, 2025
Downgrades: Underperform
Price Target: $112 → $4
Current: $2.20
Upside: +81.82%
Oct 31, 2024
Maintains: Buy
Price Target: $1,150 → $1,100
Current: $992.92
Upside: +10.78%
Oct 30, 2024
Downgrades: Underperform
Price Target: $120 → $20
Current: $28.25
Upside: -29.20%
Oct 18, 2024
Upgrades: Buy
Price Target: $22 → $31
Current: $22.63
Upside: +36.99%
Apr 17, 2024
Maintains: Neutral
Price Target: $180 → $170
Current: $201.75
Upside: -15.74%
Jan 3, 2024
Downgrades: Neutral
Price Target: $68 → $60
Current: $51.75
Upside: +15.94%
Aug 21, 2023
Maintains: Underperform
Price Target: $10 → $8
Current: $5.20
Upside: +53.85%
Aug 21, 2023
Maintains: Buy
Price Target: $19 → $17
Current: $1.55
Upside: +1,000.32%
Nov 1, 2022
Downgrades: Underperform
Price Target: $24
Current: $2.15
Upside: +1,018.62%
Jun 8, 2022
Downgrades: Neutral
Price Target: $12 → $4
Current: $11.22
Upside: -64.35%
Aug 10, 2021
Initiates: Buy
Price Target: $28
Current: $3.38
Upside: +729.63%
Jul 13, 2021
Initiates: Buy
Price Target: $34
Current: $0.55
Upside: +6,110.05%
Jan 15, 2021
Downgrades: Neutral
Price Target: $35
Current: $3.94
Upside: +788.32%
Nov 23, 2020
Initiates: Buy
Price Target: $525
Current: $27.83
Upside: +1,786.45%
Oct 20, 2020
Initiates: Buy
Price Target: $42
Current: $1.19
Upside: +3,444.30%
Sep 15, 2020
Reinstates: Buy
Price Target: $20
Current: $8.68
Upside: +130.41%
Sep 8, 2020
Reinstates: Buy
Price Target: $20
Current: $0.50
Upside: +3,902.40%
Jun 25, 2020
Reinstates: Underperform
Price Target: $9
Current: $5.37
Upside: +67.75%
Jun 25, 2020
Reinstates: Buy
Price Target: $60
Current: $13.35
Upside: +349.54%
Aug 5, 2019
Maintains: Equal-Weight
Price Target: $15 → $23
Current: $26.31
Upside: -12.58%
May 3, 2019
Downgrades: Equal-Weight
Price Target: $90 → $82
Current: $97.94
Upside: -16.28%
Mar 1, 2019
Maintains: Underweight
Price Target: $100 → $95
Current: $478.06
Upside: -80.13%
Dec 20, 2018
Downgrades: Equal-Weight
Price Target: $300 → $80
Current: $17.00
Upside: +370.59%
Aug 1, 2018
Maintains: Overweight
Price Target: $100 → $135
Current: $155.73
Upside: -13.31%
May 21, 2018
Downgrades: Underweight
Price Target: n/a
Current: $10.93
Upside: -
May 3, 2018
Maintains: Equal-Weight
Price Target: $16 → $20
Current: $3.53
Upside: +466.57%
Apr 5, 2018
Downgrades: Equal-Weight
Price Target: n/a
Current: $10.61
Upside: -
Nov 8, 2017
Maintains: Overweight
Price Target: $127 → $158
Current: $430.39
Upside: -63.29%